Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)Depreciation ExpenseEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

NRX Pharmaceuticals (NRXP) Receivables - Net (2024 - 2025)

NRX Pharmaceuticals (NRXP) has disclosed Receivables - Net for 2 consecutive years, with $161000.0 as the latest value for Q4 2025.

  • Quarterly Receivables - Net changed N/A to $161000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $161000.0 through Dec 2025, changed N/A year-over-year, with the annual reading at $161000.0 for FY2025, N/A changed from the prior year.
  • Receivables - Net for Q4 2025 was $161000.0 at NRX Pharmaceuticals, down from $239000.0 in the prior quarter.
  • The five-year high for Receivables - Net was $239000.0 in Q3 2025, with the low at $6000.0 in Q1 2024.